PUBLISHER: Grand View Research | PRODUCT CODE: 1888603
PUBLISHER: Grand View Research | PRODUCT CODE: 1888603
India Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Test Location, By Technology, By Platform, By Application, By End Use, And Segment Forecasts, 2025 - 2033
Market Size & Trends:
The India molecular diagnostics market size was estimated at USD 1,054.80 million in 2024 and is projected to reach USD 1,717.27 million by 2033, growing at a CAGR of 5.63% from 2025 to 2033. The growth is attributed to an ever-increasing burden of infectious diseases, heightened awareness of early disease detection, and greater access to advanced diagnostic technologies within healthcare settings. PCR-based assays and sample-to-answer platforms are quickly gaining market share due to their accuracy, speed, and usability in decentralized testing sites.
Moreover, the rising incidence of infectious diseases in India is one of the primary factors impacting the India molecular diagnostics industry, particularly for polymerase chain reaction (PCR) testing. Diseases, including tuberculosis (TB), hepatitis, HIV, and vector-borne diseases such as malaria and dengue, continue to be important public health problems. According to the National Tuberculosis Elimination Programme (NTEP), there were approximately 4.4 lakh deaths linked to TB in 2021, which was nearly 29% of TB-related deaths globally. The burden of these diseases necessitates the use of new diagnostic technologies, such as PCR, to ensure accurate detection in a timely manner, allowing patients to receive treatment and enabling control measures to be implemented. In India, roughly 10 million people die every year, and nearly one-fourth of these deaths-over 2.34 million deaths-are due to communicable diseases. Within this group, respiratory infections, specifically influenza and pneumonia, are the leading causes of death and represent the greatest risk to young children and elderly individuals. While respiratory infections have always accounted for the largest share of deaths due to communicable diseases, respiratory infections showed an increase in their impact in the time period of 2020 to 2022 during the COVID-19 pandemic.
The rapid expansion of personalized medicine, oncology, and genetic testing has propelled the growth of the molecular diagnostics market in India. Personalized medicine is a novel approach to medical treatment that considers individual characteristics, such as genetic information, lifestyle, and environment, to develop medicines that are more effective, precise, and targeted to the individual. Promising forces propelling the growth include the advancement of genomic technologies, an increase in the prevalence of chronic and genetic diseases, and rising awareness and demand for personalized medicine. PCR-based products, such as Truenat MTB/RIF, Roche Cobas EGFR Mutation Test, and Qiagen Therascreen KRAS/NRAS PCR kits, are helping clinicians make genomic testing a success, supporting precision treatment plans.
In oncology, the movement toward personalized treatment approaches has transformed cancer management in India. Common cancer therapy typically takes a uniform approach that is not always effective for the patient. Personalized treatment established through genomic profiling allows oncologists to choose therapies that are more likely to be effective based on the genetic profiles of the patient and the tumor. For example, targeted therapies such as Osimertinib for EGFR mutations or trastuzumab for HER2-positive breast cancer utilize specific PCR tests, including Roche Cobas (EGFR) and Qiagen (HER2) PCR kits, to identify suitable candidates. These PCR-based diagnostics enable the rapid and precise identification of mutations, facilitating timely and personalized therapy, which in turn leads to better outcomes and a lower likelihood of side effects in some patients.
Moreover, government initiatives and public-private partnerships (PPPs) have played a crucial role in developing laboratory infrastructure across India. For example, the Pradhan Mantri Jan Arogya Yojana (PMJAY) aims to provide more universal and affordable healthcare services to underprivileged populations, thereby increasing demand for diagnostic services. In partnerships like those in Rajasthan, private companies manage laboratories, install high-quality diagnostic machines, and provide online reporting using Laboratory Information Management Systems (LIMS). This results in more testing capacity, faster turnaround times, and higher accessibility in semi-urban and rural locations. The Ministry of Health and Family Welfare, Government of India highlights the massive scale-up of new TB laboratory capacity: There was an increase of 80% in Designated Microscopy Centers (DMCs) from 13,583 in 2014 to 24,573 in 2023, along with 6,496 new molecular diagnostic laboratories, and 81 Culture and Drug Susceptibility Testing (DST) laboratories by 2023, demonstrating remarkable growth of the molecular diagnostic infrastructure across India.
Additionally, the rise in the presence of private diagnostic chains has significantly contributed to the market's growth. Major players, such as Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies, are deliberately expanding their presence in towns classified as Tier 2, Tier 3, and even Tier 4, thereby providing more connection and access to urban as well as rural healthcare in India. Similarly, Co-Diagnostics, Inc. announced the opening of the oligonucleotide synthesis facility of CoSara Diagnostics Pvt. Ltd. in December 2024 in Ranoli, India. As part of the "Make in India" initiative, this facility will produce Co-Dx's patented Co-Primers chemistry used in their laboratory-based PCR tests, as well as at-home and point-of-care PCR testing platforms. Localizing production enables Co-Dx to have better access to India's large and expanding healthcare systems, while also supporting domestic manufacturing and ensuring regulatory compliance.
In conclusion, the molecular diagnostics market in India is rapidly evolving, driven by the push for personalized medicine, the introduction of new oncology therapies, and advancements in genomic technologies. Strong government support, the expansion of private diagnostic networks, and domestic manufacturing through the "Make in India" campaign are improving accessibility and infrastructure. All these factors are establishing an ecosystem positioning India as a destination for precision diagnostics and next-generation healthcare.
India Molecular Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the India molecular diagnostics market report based on product, application, technology, test location, platform, and end use:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Reagents and Consumables
- Others
- Test Location Outlook (Revenue, USD Million, 2021 - 2033)
- Point of Care
- Self-Test or OTC
- Central Laboratories
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Polymerase Chain Reaction (PCR)
- Multiplex PCR
- Real-Time PCR
- Open PCR
- Others
- Platform Outlook (Revenue, USD Million, 2021 - 2033)
- Sample-to-answer
- High-throughput Closed Systems
- Open PCR / LDT Platforms
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Gastrointestinal Infections
- Enteric Bacterial
- Salmonella
- Shigella
- Campylobacter
- E. Coli
- Others
- Enteric Viral
- Norovirus
- Rotavirus
- Adenovirus
- Astrovirus
- Sapovirus
- Enteric Parasitic
- Giardia Lamblia
- Cryptosporidium spp.
- Entamoeba Histolytica
- Respiratory Infections
- Viral Respiratory Infections
- Influenza A & B
- SARS-CoV-2
- RSV
- Human Metapneumovirus
- Parainfluenza
- Adenovirus
- Rhinovirus / Enterovirus
- Others
- Bacterial Respiratory Infections
- Mycobacterium Tuberculosis
- Bordetella Pertussis
- Mycoplasma Pneumoniae
- Chlamydophila Pneumoniae
- Others
- Healthcare-Associated Infections
- MRSA
- Clostridium Difficile
- Carbapenemase-Producing Organisms (CPO)
- Others
- Sexually Transmitted Infections & Women's Health
- HIV
- Neisseria Gonorrhoeae
- Hepatitis B (HBV)
- Hepatitis C (HCV)
- Trichomonas Vaginalis
- Mycoplasma Genitalium
- HSV
- HPV
- Group B Streptococcus (GBS)
- Chlamydia Trachomatis
- Syphilis
- Others
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Others
Table of Contents
Chapter 1. India Molecular Diagnostics Market: Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. Test Location Segment
- 1.1.1.3. Technology Segment
- 1.1.1.4. Platform Segment
- 1.1.1.5. Application Segment
- 1.1.1.6. End-use Segment
- 1.1.1. Segment Definitions
- 1.2. Estimates and Forecast Timeline
- 1.3. Objectives
- 1.3.1. Objective - 1
- 1.3.2. Objective - 2
- 1.3.3. Objective - 3
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information or Data Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations
Chapter 2. India Molecular Diagnostics Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Product and Test Location Snapshot
- 2.3. Technology and End Use Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. India Molecular Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Rising burden of infectious diseases
- 3.4.2. Expansion of personalized medicine, oncology, and genetic testing
- 3.4.3. Laboratory expansion and infrastructure development
- 3.5. Market Restraint Analysis
- 3.5.1. High cost of molecular testing and equipment
- 3.5.2. Limited skilled workforce and technical expertise
- 3.6. Market Opportunity Analysis
- 3.6.1. Government initiatives and external funding
- 3.6.2. Growing demand for multiplex and syndromic PCR panels
- 3.6.3. Technological advancements and automation in PCR platforms
- 3.7. Market Challenges Analysis
- 3.7.1. Regulatory and standardization challenges
- 3.7.2. Limited access in rural areas
- 3.8. Platform Usage And Pricing Analysis
- 3.9. Identification Of Assay Gaps & Unmet Needs
- 3.10. Porter's Five Forces Analysis
- 3.11. PESTLE Analysis
Chapter 4. India Molecular Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. India Molecular Diagnostics Market: Product Movement Analysis
- 4.2. Instruments
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Reagents and Consumables
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Others
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. India Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
- 5.1. India Molecular Diagnostics Market: Test Location Movement Analysis
- 5.2. Point of Care
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. Self-Test or OTC
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Central Laboratories
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. India Molecular Diagnostics Market: Technology Estimates & Trend Analysis
- 6.1. India Molecular Diagnostics Market: Technology Movement Analysis
- 6.2. Polymerase Chain Reaction (PCR)
- 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. Multiplex PCR
- 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. Real-Time PCR
- 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Open PCR
- 6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Others
- 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. India Molecular Diagnostics Market: Platform Estimates & Trend Analysis
- 7.1. India Molecular Diagnostics Market: Platform Movement Analysis
- 7.2. Sample-to-answer
- 7.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3. High-throughput Closed Systems
- 7.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Open PCR/LDT Platforms
- 7.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. India Molecular Diagnostics Market: Application Estimates & Trend Analysis
- 8.1. India Molecular Diagnostics Market: Application Movement Analysis
- 8.2. Gastrointestinal Infections
- 8.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2. Enteric Bacterial
- 8.2.2.1. Salmonella
- 8.2.2.1.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2.2. Shigella
- 8.2.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2.3. Campylobacter
- 8.2.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2.4. E. Coli
- 8.2.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2.5. Others
- 8.2.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.2.1. Salmonella
- 8.2.3. Enteric Viral
- 8.2.3.1. Norovirus
- 8.2.3.1.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.3.2. Rotavirus
- 8.2.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.3.3. Adenovirus
- 8.2.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.3.4. Astrovirus
- 8.2.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.3.5. Sapovirus
- 8.2.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.3.1. Norovirus
- 8.2.4. Enteric Parasitic
- 8.2.4.1. Giardia Lamblia
- 8.2.4.1.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.4.2. Cryptosporidium spp.
- 8.2.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.4.3. Entamoeba Histolytica
- 8.2.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.2.4.1. Giardia Lamblia
- 8.3. Respiratory Infections
- 8.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Viral Respiratory Infections
- 8.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.2. Influenza A & B
- 8.3.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.3. SARS-CoV-2
- 8.3.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.4. RSV
- 8.3.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.5. Human Metapneumovirus
- 8.3.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.6. Parainfluenza
- 8.3.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.7. Adenovirus
- 8.3.2.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.8. Rhinovirus / Enterovirus
- 8.3.2.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2.9. Others
- 8.3.2.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3. Bacterial Respiratory Infections
- 8.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3.2. Mycobacterium Tuberculosis
- 8.3.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3.3. Bordetella Pertussis
- 8.3.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3.4. Mycoplasma Pneumoniae
- 8.3.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3.5. Chlamydophila Pneumoniae
- 8.3.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.3.6. Others
- 8.3.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4. Healthcare-Associated Infections
- 8.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. MRSA
- 8.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Clostridium Difficile
- 8.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Carbapenemase-Producing Organisms (CPO)
- 8.4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.5. Others
- 8.4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Sexually Transmitted Infections & Women's Health
- 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. HIV
- 8.5.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Neisseria Gonorrhoeae
- 8.5.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. Hepatitis B (HBV)
- 8.5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Hepatitis C (HCV)
- 8.5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Trichomonas Vaginalis
- 8.5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Mycoplasma Genitalium
- 8.5.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. HSV
- 8.5.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. HPV
- 8.5.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.10. Group B Streptococcus (GBS)
- 8.5.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.11. Chlamydia Trachomatis
- 8.5.11.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.12. Syphilis
- 8.5.12.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.13. Others
- 8.5.13.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Others
- 8.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. India Molecular Diagnostics Market: End Use Estimates & Trend Analysis
- 9.1. India Molecular Diagnostics Market: End Use Movement Analysis
- 9.2. Hospitals & Clinics
- 9.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3. Diagnostic Laboratories
- 9.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Academic & Research Institutes
- 9.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Others
- 9.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Strategy Mapping
- 10.2.1. New Product Launch
- 10.2.2. Partnerships
- 10.2.3. Acquisition
- 10.2.4. Collaboration
- 10.2.5. Funding
- 10.3. Key Company Market Share Analysis, 2024
- 10.4. Company Heat Map Analysis
- 10.5. Company Profiles
- 10.5.1. Cepheid (Danaher Corporation)
- 10.5.1.1. Company Overview
- 10.5.1.2. Financial Performance
- 10.5.1.3. Product Benchmarking
- 10.5.1.4. Strategic Initiatives
- 10.5.2. BioFire Diagnostics (BIOMERIEUX)
- 10.5.2.1. Company Overview
- 10.5.2.2. Financial Performance
- 10.5.2.3. Product Benchmarking
- 10.5.2.4. Strategic Initiatives
- 10.5.3. Abbott
- 10.5.3.1. Company Overview
- 10.5.3.2. Financial Performance
- 10.5.3.3. Product Benchmarking
- 10.5.3.4. Strategic Initiatives
- 10.5.4. QIAGEN
- 10.5.4.1. Company Overview
- 10.5.4.2. Financial Performance
- 10.5.4.3. Product Benchmarking
- 10.5.4.4. Strategic Initiatives
- 10.5.5. F.Hoffmann-La Roche Ltd
- 10.5.5.1. Company Overview
- 10.5.5.2. Financial Performance
- 10.5.5.3. Product Benchmarking
- 10.5.5.4. Strategic Initiatives
- 10.5.6. Agilent Technologies
- 10.5.6.1. Company Overview
- 10.5.6.2. Financial Performance
- 10.5.6.3. Product Benchmarking
- 10.5.6.4. Strategic Initiatives
- 10.5.7. Bio-Rad Laboratories, Inc.
- 10.5.7.1. Company Overview
- 10.5.7.2. Financial Performance
- 10.5.7.3. Product Benchmarking
- 10.5.7.4. Strategic Initiatives
- 10.5.8. Sysmex Corporation
- 10.5.8.1. Company Overview
- 10.5.8.2. Financial Performance
- 10.5.8.3. Product Benchmarking
- 10.5.8.4. Strategic Initiatives
- 10.5.9. Seegene Inc.
- 10.5.9.1. Company Overview
- 10.5.9.2. Financial Performance
- 10.5.9.3. Product Benchmarking
- 10.5.9.4. Strategic Initiatives
- 10.5.10. 3B BlackBio Dx Ltd. (TRUPCR)
- 10.5.10.1. Company Overview
- 10.5.10.2. Financial Performance
- 10.5.10.3. Product Benchmarking
- 10.5.10.4. Strategic Initiatives
- 10.5.11. Mylab Discovery Solutions Pvt. Ltd
- 10.5.11.1. Company Overview
- 10.5.11.2. Financial Performance
- 10.5.11.3. Product Benchmarking
- 10.5.11.4. Strategic Initiatives
- 10.5.12. altona Diagnostics
- 10.5.12.1. Company Overview
- 10.5.12.2. Financial Performance
- 10.5.12.3. Product Benchmarking
- 10.5.12.4. Strategic Initiatives
- 10.5.1. Cepheid (Danaher Corporation)
List of Tables
- Table 1 List Of Abbreviations
- Table 2 India Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
- Table 3 India Molecular Diagnostics Market, By Test Location, 2021 - 2033 (USD Million)
- Table 4 India Molecular Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
- Table 5 India Molecular Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
- Table 6 India Molecular Diagnostics Market, By Platform, 2021 - 2033 (USD Million)
- Table 7 India Molecular Diagnostics Market, By Application, 2021 - 2033 (USD Million)
List Of Figures
- Fig. 1 Market Research Process
- Fig. 2 Information Procurement
Fig. 3 Market Summary
- Fig. 4 Market Segmentation & Scope
- Fig. 5 Market Size and Growth Prospects
- Fig. 6 India Molecular Diagnostics Market - Key Market Driver Analysis
- Fig. 7 India Molecular Diagnostics Market - Key Market Restraint Analysis
- Fig. 8 Penetration & Growth Prospect Mapping
- Fig. 9 India Molecular Diagnostics Market - Porter's Analysis
- Fig. 10 India Molecular Diagnostics Market - PESTEL Analysis
- Fig. 11 India Molecular Diagnostics Market Product Outlook Key Takeaways
- Fig. 12 India Molecular Diagnostics Market: Product Movement Analysis
- Fig. 13 Instruments Market Estimates, 2021 - 2033 (USD Million)
- Fig. 14 Reagents and Consumables Market Estimates, 2021 - 2033 (USD Million)
- Fig. 15 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 16 India Molecular Diagnostics Market Test Location Outlook Key Takeaways
- Fig. 17 India Molecular Diagnostics Market: Test Location Movement Analysis
- Fig. 18 Point of Care Market Estimates, 2021 - 2033 (USD Million)
- Fig. 19 Self-Test or OTC Market Estimates, 2021 - 2033 (USD Million)
- Fig. 20 Central Laboratories Market Estimates, 2021 - 2033 (USD Million)
- Fig. 21 India Molecular Diagnostics Market Technology Outlook Key Takeaways
- Fig. 22 India Molecular Diagnostics Market: Technology Movement Analysis
- Fig. 23 Polymerase Chain Reaction (PCR) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 24 Multiplex PCR Market Estimates, 2021 - 2033 (USD Million)
- Fig. 25 Real-Time PCR Market Estimates, 2021 - 2033 (USD Million)
- Fig. 26 Open PCR Market Estimates, 2021 - 2033 (USD Million)
- Fig. 27 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 28 India Molecular Diagnostics Market Platform Outlook Key Takeaways
- Fig. 29 India Molecular Diagnostics Market: Platform Movement Analysis
- Fig. 30 Sample-to-answer Market Estimates, 2021 - 2033 (USD Million)
- Fig. 31 High-throughput Closed Systems Market Estimates, 2021 - 2033 (USD Million)
- Fig. 32 Open PCR/LDT Platforms Market Estimates, 2021 - 2033 (USD Million)
- Fig. 33 India Molecular Diagnostics Market Application Outlook Key Takeaways
- Fig. 34 India Molecular Diagnostics Market: Application Movement Analysis
- Fig. 35 Polymerase Chain Reaction (PCR) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 36 Gastrointestinal Infections Market Estimates, 2021 - 2033 (USD Million)
- Fig. 37 Enteric Bacterial Market Estimates, 2021 - 2033 (USD Million)
- Fig. 38 Salmonella Market Estimates, 2021 - 2033 (USD Million)
- Fig. 39 Shigella Market Estimates, 2021 - 2033 (USD Million)
- Fig. 40 Campylobacter Market Estimates, 2021 - 2033 (USD Million)
- Fig. 41 E. Coli Market Estimates, 2021 - 2033 (USD Million)
- Fig. 42 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 43 Norovirus Viral Market Estimates, 2021 - 2033 (USD Million)
- Fig. 44 Rotavirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 45 Adenovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 46 Astrovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 47 Sapovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 48 Enteric Parasitic Market Estimates, 2021 - 2033 (USD Million)
- Fig. 49 Giardia Lamblia Market Estimates, 2021 - 2033 (USD Million)
- Fig. 50 Cryptosporidium spp. Market Estimates, 2021 - 2033 (USD Million)
- Fig. 51 Entamoeba Histolytica Market Estimates, 2021 - 2033 (USD Million)
- Fig. 52 Respiratory Infections Market Estimates, 2021 - 2033 (USD Million)
- Fig. 53 Viral Respiratory Infections Market Estimates, 2021 - 2033 (USD Million)
- Fig. 54 Influenza A & B Market Estimates, 2021 - 2033 (USD Million)
- Fig. 60 SARS-CoV-2 Market Estimates, 2021 - 2033 (USD Million)
- Fig. 61 RSV Market Estimates, 2021 - 2033 (USD Million)
- Fig. 62 Human Metapneumovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 63 Parainfluenza Market Estimates, 2021 - 2033 (USD Million)
- Fig. 64 Adenovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 65 Rhinovirus / Enterovirus Market Estimates, 2021 - 2033 (USD Million)
- Fig. 66 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 67 Bacterial Respiratory Infections Market Estimates, 2021 - 2033 (USD Million)
- Fig. 68 Mycobacterium Tuberculosis Market Estimates, 2021 - 2033 (USD Million)
- Fig. 69 Bordetella Pertussis Market Estimates, 2021 - 2033 (USD Million)
- Fig. 70 Mycoplasma Pneumoniae Market Estimates, 2021 - 2033 (USD Million)
- Fig. 71 Chlamydophila Pneumoniae Market Estimates, 2021 - 2033 (USD Million)
- Fig. 72 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 73 Healthcare-Associated Infections Market Estimates, 2021 - 2033 (USD Million)
- Fig. 74 MRSA Market Estimates, 2021 - 2033 (USD Million)
- Fig. 75 Clostridium Difficile Market Estimates, 2021 - 2033 (USD Million)
- Fig. 76 Carbapenemase-Producing Organisms (CPO) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 77 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 78 Sexually Transmitted Infections & Women's Health Market Estimates, 2021 - 2033 (USD Million)
- Fig. 79 HIV Market Estimates, 2021 - 2033 (USD Million)
- Fig. 80 Neisseria Gonorrhoeae Market Estimates, 2021 - 2033 (USD Million)
- Fig. 81 Hepatitis B (HBV) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 82 Hepatitis C (HCV) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 83 Trichomonas Vaginalis Market Estimates, 2021 - 2033 (USD Million)
- Fig. 84 Mycoplasma Genitalium Market Estimates, 2021 - 2033 (USD Million)
- Fig. 85 HSV Market Estimates, 2021 - 2033 (USD Million)
- Fig. 86 HPV Market Estimates, 2021 - 2033 (USD Million)
- Fig. 87 Group B Streptococcus (GBS) Market Estimates, 2021 - 2033 (USD Million)
- Fig. 88 Chlamydia Trachomatis Market Estimates, 2021 - 2033 (USD Million)
- Fig. 89 Syphilis Market Estimates, 2021 - 2033 (USD Million)
- Fig. 90 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 91 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 92 End Use Market Estimates, 2021 - 2033 (USD Million)
- Fig. 93 End Use Market Estimates, 2021 - 2033 (USD Million)
- Fig. 94 Hospitals & Clinics Market Estimates, 2021 - 2033 (USD Million)
- Fig. 95 Diagnostic Laboratories Market Estimates, 2021 - 2033 (USD Million)
- Fig. 96 Academic & Research Institutes Market Estimates, 2021 - 2033 (USD Million)
- Fig. 97 Others Market Estimates, 2021 - 2033 (USD Million)
- Fig. 98 Strategy Framework
